AstraZeneca, Daiichi Sankyo, Summit to test Datroway with ivonescimab combo
The companies plan to start with a Phase III trial in first-line triple-negative breast cancer, per a filing dated October 2, 2026.
AstraZeneca and Daiichi Sankyo have entered a clinical collaboration agreement with Summit Therapeutics Inc. to study the antibody drug conjugate Datroway (datopotamab deruxtecan) alongside the bispecific antibody ivonescimab in several tumor types, among them lung and breast cancers, according to a 6-K filing dated October 2, 2026. AstraZeneca and Daiichi Sankyo have entered into a clinical collaboration agreement with Summit Therapeutics Inc. to evaluate Datroway (datopotamab deruxtecan) in combination with ivonescimab across multiple tumour types including lung and breast cancers.1 The first planned study, per the companies, will be a Phase III trial in 1st-line triple-negative breast cancer (TNBC).1
Under the deal, each company will contribute its respective medicine for the planned combination trials, which will be sponsored by AstraZeneca or Daiichi Sankyo, with all three companies sharing trial costs while each retains development and commercial rights to its own medicine.1 The filing notes AstraZeneca recently made an equity investment intended in part to support clinical collaborations evaluating ivonescimab combinations, including this Datroway agreement and a separate AstraZeneca-Summit agreement covering combinations with sonesitatug vedotin (Sone-Ve).1
On ivonescimab's status, the filing describes it as a bispecific molecule designed to block both PD-1 and VEGF activity in one agent, and states that it is approved to treat certain patients with non-small cell lung cancer (NSCLC) in China, with a Biologics License Application seeking approval in EGFR-mutated NSCLC under review by the US FDA.1 It is also being studied in Phase III trials across NSCLC, small cell lung cancer, biliary tract cancer, bladder cancer, TNBC, head and neck squamous cell carcinoma, colorectal cancer, and pancreatic cancer.1
On the underlying drug relationship, the filing states AstraZeneca and Daiichi Sankyo struck their original partnership covering the ADC jointly in 2019 for Enhertu and extended it to Datroway the following year, with Daiichi Sankyo retaining exclusive rights to each ADC in Japan.1 Daiichi Sankyo remains responsible for manufacturing and supply of both Enhertu and Datroway.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.